Back to library
CognitiveSubcutaneous
BDNF
Also known as: Brain-Derived Neurotrophic Factor
247-amino-acid neurotrophin secreted by neurons. Binds TrkB to drive synaptic plasticity, long-term potentiation, and neurogenesis in the hippocampus and prefrontal cortex. Recombinant BDNF has poor blood-brain barrier penetration — most therapeutic strategies use BDNF mimetics or pathway activators rather than direct administration.
At a glance
- Half-life
- 12 minutes
- Common route
- Subcutaneous
- Typical dose range
- 50–500mcg
- Stability (reconstituted)
- 7days refrigerated
Best timing
Native BDNF clears within minutes from circulation and does not effectively cross BBB. Research peptide use is largely investigational and pharmacokinetically limited.
Contraindications
- Active cancer (TrkB is upregulated in some tumors)
- Pregnancy
- Chronic pain syndromes
- No established human clinical use of injectable recombinant BDNF
Watch symptoms
- Limited human characterization for injectable BDNF
- Theoretical peripheral neuropathic effects
- Injection site reactions
- Pharmacokinetic limitations — most effect requires CNS delivery routes not available outside research
Citations